Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA)

Anti-Cancer Drug Design

Volumn 14, Issue 3, 1999, Pages 275-280

  Haldane, Andrea ^a   Finlay, Graeme J ^a   Hay, Michael P ^a   Denny, William A ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antitumour; Intercalation; Lipophilicity; Multidrug resistance; Topoisomerase

Indexed keywords

ACRIDINE DERIVATIVE; AMIDE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; INTERCALATING AGENT; OCTANOL; POISON; TRITIUM; WATER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOPLASM; DRUG DNA BINDING; DRUG UPTAKE; FLUORESCENCE MICROSCOPY; FLUOROMETRY; HUMAN; HUMAN CELL; HYDROPHILICITY; LEUKEMIA P 388; LEWIS CARCINOMA; LIPOPHILICITY; MEMBRANE VESICLE; MULTIDRUG RESISTANCE; PARTITION COEFFICIENT; PRIORITY JOURNAL; TRANSPORT KINETICS;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; INTERCALATING AGENTS; LEUKEMIA P388; MICE; TRITIUM; TUMOR CELLS, CULTURED;

TRITIUM;

EID: 0032855989     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Allen L.M. (1978) Comparison of uptake and binding of two epipodophyllotoxin glycopyranosides, 4′-demethyl epipodophyllotoxin thienylide-β-D-glucoside and 4′-demethyl ethylene-β-D-glucoside in the L1210 leukemia cell. Cancer Research, 38, 2549.
2. Almquist K.C., Loe D.W., Hipfner D.R., Mackie J.E., Cole S.P.C., Deeley R.G. (1995) Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Research, 55, 102.
3. Atwell G.J., Cain B.F., Baguley B.C., Finlay G.J., Denny W.A. (1984) Potential antitumor agents. Part 43. Synthesis and biological activity of dibasic 4-carboxamido-9-amino-acridines, a new class of antitumor agent. Journal of Medicinal Chemistry, 27, 1481.
4. Atwell G.J., Rewcastle G.W., Baguley B.C., Denny W.A. (1987) Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Journal of Medicinal Chemistry, 30, 664.
5. Baguley B.C., Finlay, G.J. (1988a) Derivatives of amsacrine: determinants required for high activity against the Lewis lung carcinoma. Journal of the National Cancer Institute, 80, 195.
6. Baguley B.C., Finlay G.J. (1988b) Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to Adriamycin-resistant P388 leukemia cells. European Journal of Cancer and Clinical Oncology, 24, 205.
7. Baguley B.C., Holdaway K.M., Fray L.M. (1990) Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance. Journal of the National Cancer Institute, 82, 398.
8. Baguley B.C., Zhuang L., Marshall E. (1995) Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide. Cancer Chemotherapy and Pharmacology, 36, 244.
9. Chevallier-Multon M.-C., Jacquemin-Sablon A., Besselièvre R., Husson H.-P., Le Pecq J.-B. (1990) Comparative cytotoxicities of a series of ellipticine and olivacine derivatives on multidrug resistant cells of human and murine origins. Anti-Cancer Drug Design, 5, 319.
10. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., Deeley R.G. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650.
11. Crenshaw J.M., Graves D.E., Denny W.A. (1995) Interactions of acridine antitumor agents with DNA: binding energies and groove preferences. Biochemistry, 34, 13682.
12. Davey R.A., Su G.M., Hargrave R.M., Harvie R.M., Baguley B.C., Davey M.W. (1997) The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemotherapy and Pharmacology, 39, 424.
13. de Bono J.S., Propper D., Ellard S., Steiner J., Bevan P., Dobbs N., Flannigan E., Ganesan T.S., Talbot D.C., Campbell S., Twelves C., Harris A. (1998) A phase I study of XR5000 (DACA) by 120 h intravenous infusion. In Proceedings of the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, p. 449.
14. Denny W.A., Atwell G.J., Rewcastle G.W., Baguley B.C. (1987) Potential antitumor agents. 49. 5-Substituted derivatives of N-[2-(dimethylamino)ethyl]9-aminoacridine-4-carboxamide with in vivo solid tumor activity. Journal of Medicinal Chemistry, 30, 658.
15. Evans S.M.H., Robertson I.G.C., Paxton J.W. (1994) Plasma protein binding of the experimental antitumour agent acridine-4-carboxamide in man, dog, rat and rabbit. Journal of Pharmacy and Pharmacology, 46, 63.
16. Finlay G.J., Baguley B.C. (1989) Selectivity of N-[2-(dimethyl-amino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro. European Journal of Cancer and Clinical Oncology, 25, 271.
17. Finlay G.J., Wilson W.R., Baguley B.C. (1989) Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. European Journal of Cancer and Clinical Oncology, 25, 1695.
18. Finlay G.J., Baguley B.C., Snow K., Judd W. (1990) Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. Journal of the National Cancer Institute, 82, 662.
19. Finlay G.J., Marshall E.S., Matthews J.H.L., Paull K.D., Baguley B.C. (1993) In vitro assessment of N-[2-(dimethyl-amino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemotherapy and Pharmacology, 31, 401.
20. Finlay G.J., Riou J.-F., Baguley B.C. (1996) From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. European Journal of Cancer, 32A, 708.
21. Granzen B., Graves D.E., Baguley B.C., Danks M.K., Beck W.T. (1992) Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase-II or P-glycoprotein. Oncology Research, 4, 489.
22. Haldane A., Finlay G.J., Gavin J.B., Baguley B.C. (1992) Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethyl-amino)ethyl]acridine-4-carboxamide. Cancer Chemotherapy and Pharmacology, 29, 475.
23. Hendricks C.B., Rowinsky E.K., Grochow L.B., Donehower R.C., Kaufmann S.H. (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SKandF-104864), a new camptothecin analogue. Cancer Research, 52, 2268.
24. Kartner N., Riordan J.R., Ling V. (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science, 221, 1285.
25. Klohs W.D., Steinkampf R.W., Havlick M.J., Jackson R.C. (1986) Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists. Cancer Research, 46, 4352.
26. Liley D.T.J., Wiggins P.M., Baguley B.C. (1989) Localisation of a nonintercalative DNA binding antitumour agent in mitochondria: relationship to multidrug resistance. European Journal of Cancer and Clinical Oncology, 25, 1287.
27. Ling Y.H., Priebe W., Yang L.Y., Burke T.G., Pommier Y., Perezsoler R. (1993) In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Research, 53, 1583.
28. Louie K.G., Hamilton T.C., Winker M.A., Behrens B.C., Tsuruo T., Klecker R.W. Jr, McKoy W.M., Grotzinger K.R., Myers C.E., Young R.C., Ozols R.F. (1986) Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochemical Pharmacology, 35, 467.
29. McCrystal M.R., Evans B.D., Harvey V.J., Thompson P.I., Porter D.J., Baguley B.C. (1998) A phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). Cancer Chemotherapy and Pharmacology, in press.
30. Qian X., Beck W.T. (1990) Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines. Cancer Research, 50, 1132.
31. Riordan J.R., Ling V. (1985) Genetic and biochemical characterization of MDR. Pharmacology and Therapeutics, 28, 51.
32. Robbie M.A., Baguley B.C., Denny W.A., Gavin J.B., Wilson W.R. (1988) Mechanism of resistance of non-cycling mammalian cells to 4′-(9-acridinylamino)-methane-sulfon-m-anisidide (m-AMSA): comparison of uptake, metabolism and DNA breakage in log-and plateau-phase Chinese hamster fibroblast cell cultures. Cancer Research, 48, 310.
33. Roninson I.B. (1992) The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochemical Pharmacology, 43, 95.
34. Rose W.C., Trader M.W., Laster W.R., Jr, Schabel F.M., Jr (1978) Comparative antitumor activity of actinomycin analogs in mice bearing Ridgway osteogenic sarcoma or P388 leukemia. Cancer Treatment Reports, 62, 779.
35. Schneider E., Darkin S.J., Lawson P.A., Ching L.-M., Ralph R.K., Baguley B.C. (1988) Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. European Journal of Cancer and Clinical Oncology, 24, 1783.
36. Sehested M., Skovsgaard T., van Deurs B., Winther-Nielson H. (1987) Increase in nonspecific adsorptive endocytosis in anthracycline-and Vinca alkaloid-resistant Ehrlich ascites tumor cell lines. Journal of the National Cancer Institute, 78, 171.
37. Sum B.G., Denny W.A., Wilson W.R. (1994) Does DNA targeting affect the cytotoxicity and cell uptake of basic nitroquinoline bioreductive drugs? International Journal of Radiation Oncology Biology and Physics, 29, 311.